NASDAQ:COYA Coya Therapeutics (COYA) Stock Price, News & Analysis → “The Stock Market’s Bull Run is Far from Over” -Barrons (From Vertical Research Advisory) (Ad) Free COYA Stock Alerts $9.92 +0.27 (+2.80%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$9.28▼$10.0150-Day Range$5.83▼$10.1352-Week Range$3.21▼$10.69Volume122,923 shsAverage Volume95,289 shsMarket Capitalization$99.50 millionP/E RatioN/ADividend YieldN/APrice Target$14.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get Coya Therapeutics alerts: Email Address Coya Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside41.1% Upside$14.00 Price TargetShort InterestHealthy0.38% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.06Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.32 out of 5 starsMedical Sector782nd out of 938 stocksPharmaceutical Preparations Industry352nd out of 422 stocks 3.5 Analyst's Opinion Consensus RatingCoya Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $14.00, Coya Therapeutics has a forecasted upside of 41.1% from its current price of $9.92.Amount of Analyst CoverageCoya Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.38% of the float of Coya Therapeutics has been sold short.Short Interest Ratio / Days to CoverCoya Therapeutics has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Coya Therapeutics has recently increased by 123.44%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCoya Therapeutics does not currently pay a dividend.Dividend GrowthCoya Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for COYA. Previous Next 1.6 News and Social Media Coverage News SentimentCoya Therapeutics has a news sentiment score of -0.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Coya Therapeutics this week, compared to 2 articles on an average week.Search Interest12 people have searched for COYA on MarketBeat in the last 30 days. This is an increase of 500% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Coya Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Coya Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders12.00% of the stock of Coya Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 39.75% of the stock of Coya Therapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Coya Therapeutics is -12.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Coya Therapeutics is -12.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCoya Therapeutics has a P/B Ratio of 2.79. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Vertical Research Advisory“The Stock Market’s Bull Run is Far from Over” -BarronsBarron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!Click here for all the details now… About Coya Therapeutics Stock (NASDAQ:COYA)Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous and/or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.Read More COYA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart COYA Stock News HeadlinesMarch 27, 2024 | finance.yahoo.comWe're Not Very Worried About Coya Therapeutics' (NASDAQ:COYA) Cash Burn RateMarch 27, 2024 | americanbankingnews.comCritical Survey: Coya Therapeutics (COYA) versus The CompetitionMarch 29, 2024 | Vertical Research Advisory (Ad)“The Stock Market’s Bull Run is Far from Over” -BarronsBarron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!March 26, 2024 | americanbankingnews.comComparing Coya Therapeutics (COYA) and Its CompetitorsMarch 21, 2024 | finance.yahoo.comCoya Therapeutics Inc (COYA) Reports Fiscal 2023 Financial Results and Corporate UpdatesMarch 21, 2024 | americanbankingnews.comCoya Therapeutics (NASDAQ:COYA) Price Target Raised to $14.00 at Chardan CapitalMarch 19, 2024 | investorplace.comCOYA Stock Earnings: Coya Therapeutics Reported Results for Q4 2023March 19, 2024 | finance.yahoo.comCoya Therapeutics Provides a Corporate Update and Reports Fiscal 2023 Financial ResultsMarch 29, 2024 | Vertical Research Advisory (Ad)“The Stock Market’s Bull Run is Far from Over” -BarronsBarron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!March 14, 2024 | investing.comCoya presents promising ALS biomarker data at conferenceMarch 13, 2024 | msn.comNew treatment for ALS provides hope for Maine families battling diseaseMarch 12, 2024 | finance.yahoo.comCoya Therapeutics Presents ALS Biomarker Data at Society of Neuroimmune Pharmacology ConferenceMarch 12, 2024 | finance.yahoo.comCoya Therapeutics to Participate in BTIG Fireside DiscussionMarch 10, 2024 | markets.businessinsider.comBuy Recommendation for Coya Therapeutics on Promising Neurodegenerative Disease Treatment ApproachMarch 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for Dyne Therapeutics: Promising Clinical Data and Solid Financial Position Fuel OptimismFebruary 29, 2024 | finance.yahoo.comCoya Therapeutics to Present Data on Immune System and Regulatory T Cell (Treg) Contributions in Frontotemporal Dementia (FTD) Patients at AD/PD 2024 ConferenceFebruary 22, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Exact Sciences (EXAS), Denali Therapeutics (DNLI) and Treace Medical Concepts (TMCI)February 22, 2024 | msn.comCoya Inches up Ahead of ALS AddressFebruary 22, 2024 | businesswire.comCoya Therapeutics to Present Novel Biomarker Survival Data in Large Cohort of ALS (Amyotrophic Lateral Sclerosis) Patients at Society of Neuroimmune Pharmacology ConferenceFebruary 21, 2024 | finance.yahoo.comCoya Therapeutics Issues Letter to Stockholders Highlighting Expansion of COYA 302 into Alzheimer’s Disease and Coya’s Pathway to a "Pipeline in a Product"February 21, 2024 | businesswire.comCoya Therapeutics Issues Letter to Stockholders Highlighting Expansion of COYA 302 into Alzheimer's Disease and Coya's Pathway to a “Pipeline in a Product”February 13, 2024 | finance.yahoo.comCoya Therapeutics Licenses Intellectual Property Rights for Use of Next Generation Immune Modulatory Biologics in Combination with COYA 301 to Enhance Regulatory T Cells (Tregs) in Inflammatory DiseasesFebruary 5, 2024 | benzinga.comCoya Therapeutics Secures Key Financing In Its Fight Against Myriad DiseasesFebruary 1, 2024 | markets.businessinsider.comBuy Rating Affirmed for Coya Therapeutics Amid Promising Drug Development and Regulatory MilestonesJanuary 29, 2024 | finance.yahoo.comCoya Therapeutics SAB Chairman Dr. Stanley Appel, M.D. Selected as Speaker at the Society of Neuroimmune Pharmacology ConferenceJanuary 18, 2024 | finance.yahoo.comCoya Therapeutics to Participate in Upcoming Chardan Biotech Leadership Call SeriesJanuary 16, 2024 | finance.yahoo.comCoya Therapeutics Announces Pipeline Expansion of COYA 302 to Include Frontotemporal Dementia and Parkinson’s Disease in Addition to Amyotrophic Lateral SclerosisSee More Headlines Receive COYA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Coya Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today3/28/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:COYA CUSIPN/A CIK1835022 Webwww.coyatherapeutics.com Phone800-587-8170FaxN/AEmployees8Year FoundedN/APrice Target and Rating Average Stock Price Target$14.00 High Stock Price Target$14.00 Low Stock Price Target$14.00 Potential Upside/Downside+41.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.78) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,990,000.00 Net MarginsN/A Pretax Margin-121.03% Return on Equity-42.53% Return on Assets-37.57% Debt Debt-to-Equity RatioN/A Current Ratio8.15 Quick Ratio8.15 Sales & Book Value Annual Sales$6 million Price / Sales16.58 Cash FlowN/A Price / Cash FlowN/A Book Value$3.55 per share Price / Book2.79Miscellaneous Outstanding Shares10,030,000Free Float8,826,000Market Cap$99.50 million OptionableNot Optionable Beta0.78 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesDr. Howard Berman Ph.D. (Age 50)Chairman & CEO Comp: $598.12kMr. David S. Snyder (Age 64)CFO & COO Comp: $465.27kDr. Fred Grossman D.O.FAPA, President & Chief Medical OfficerDr. Gregory MacMichael Ph.D. (Age 68)Chief Technical Officer Dr. Michelle Frazier Ph.D.Senior Vice President of Regulatory AffairsMr. Aaron Thome Ph.D.Head of Neuroinflammation PlatformDr. Arun Swaminathan Ph.D.Chief Business Development OfficerMore ExecutivesKey CompetitorsCorvus PharmaceuticalsNASDAQ:CRVSCarisma TherapeuticsNASDAQ:CARMInflaRxNASDAQ:IFRXCidara TherapeuticsNASDAQ:CDTXLeap TherapeuticsNASDAQ:LPTXView All CompetitorsInstitutional OwnershipVanguard Group Inc.Bought 82,948 shares on 3/11/2024Ownership: 0.969%Greenlight Capital Inc.Bought 805,959 shares on 2/15/2024Ownership: 12.702%Vanguard Group Inc.Bought 82,948 shares on 2/15/2024Ownership: 0.969%Potomac Capital Management Inc.Bought 21,101 shares on 2/15/2024Ownership: 0.210%Citadel Advisors LLCBought 16,592 shares on 2/15/2024Ownership: 0.165%View All Institutional Transactions COYA Stock Analysis - Frequently Asked Questions Should I buy or sell Coya Therapeutics stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Coya Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" COYA shares. View COYA analyst ratings or view top-rated stocks. What is Coya Therapeutics' stock price target for 2024? 2 Wall Street research analysts have issued 1-year price objectives for Coya Therapeutics' stock. Their COYA share price targets range from $14.00 to $14.00. On average, they anticipate the company's stock price to reach $14.00 in the next year. This suggests a possible upside of 41.1% from the stock's current price. View analysts price targets for COYA or view top-rated stocks among Wall Street analysts. How have COYA shares performed in 2024? Coya Therapeutics' stock was trading at $7.41 at the beginning of the year. Since then, COYA shares have increased by 33.9% and is now trading at $9.92. View the best growth stocks for 2024 here. Are investors shorting Coya Therapeutics? Coya Therapeutics saw a increase in short interest in March. As of March 15th, there was short interest totaling 46,700 shares, an increase of 123.4% from the February 29th total of 20,900 shares. Based on an average daily trading volume, of 92,200 shares, the days-to-cover ratio is presently 0.5 days. Currently, 0.4% of the company's stock are sold short. View Coya Therapeutics' Short Interest. When is Coya Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our COYA earnings forecast. When did Coya Therapeutics IPO? Coya Therapeutics (COYA) raised $15 million in an initial public offering (IPO) on Thursday, December 29th 2022. The company issued 3,050,000 shares at a price of $5.00 per share. Who are Coya Therapeutics' major shareholders? Coya Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Greenlight Capital Inc. (12.70%), AIGH Capital Management LLC (10.29%), Vanguard Group Inc. (0.97%), Vanguard Group Inc. (0.97%), Worth Venture Partners LLC (0.92%) and Potomac Capital Management Inc. (0.21%). How do I buy shares of Coya Therapeutics? Shares of COYA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:COYA) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 Media“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyFed launches fourth dollar overhaulStansberry ResearchAI healthcare stock poised for 36,996% growth?Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coya Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.